Off-label use of intravitreal bevacizumab: A global conundrum

被引：2
作者：
Singh, Samya [1 ]
Saxena, Sandeep [1 ]
Akduman, Levent [2 ]
Meyer, Carsten H. [3 ]
机构：
[1] King Georges Med Univ, Dept Ophthalmol, Lucknow, Uttar Pradesh, India
[2] St Louis Univ, Eye Inst, Dept Ophthalmol, St. Louis, MO USA
[3] Eye Ctr, Dept Ophthalmol, Chur, Grischun, Switzerland
来源：
INDIAN JOURNAL OF OPHTHALMOLOGY | 2024年 / 72卷 / 05期
关键词：
age related macular degeneration; bevacizumab; diabetes macular edema; intravitreal injection; off-label use; MACULAR DEGENERATION; RANIBIZUMAB;
D O I：
10.4103/IJO.IJO_2166_23
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Bevacizumab is a monoclonal, humanized, full-length antibody targeting vascular endothelial growth factor(VEGF-A), known for its anti-angiogenic properties. The off-label use of bevacizumab has stirred legal, financial, industrial, and ethical complexities. With its potential to treat diverse ocular conditions, this commentary delves into the multifaceted dimensions of bevacizumab's off-label utilization, encompassing clinical trials, regulatory frameworks, safety considerations, comparative effectiveness, and economic implications.
引用
收藏
页码：617 / 619
页数：3
相关论文
共 22 条
[1]  
American Society of Retina Specialists, 2018, Preferences and trends Survey
[2]   Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol [J].
Berg, Karina ;
Pedersen, Terje R. ;
Sandvik, Leiv ;
Bragadottir, Ragnheidur .
OPHTHALMOLOGY, 2015, 122 (01) :146-152
[3]   Off-label use of bevacizumab for wet age-related macular degeneration in Europe [J].
Bro, Tomas ;
Derebecka, Magdalena ;
Jorstad, Oystein Kalsnes ;
Grzybowski, Andrzej .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 258 (03) :503-511
[4]   Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial [J].
Chakravarthy, Usha ;
Harding, Simon P. ;
Rogers, Chris A. ;
Downes, Susan M. ;
Lotery, Andrew J. ;
Culliford, Lucy A. ;
Reeves, Barnaby C. .
LANCET, 2013, 382 (9900) :1258-1267
[5]   Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial [J].
Dakin, Helen A. ;
Wordsworth, Sarah ;
Rogers, Chris A. ;
Abangma, Giselle ;
Raftery, James ;
Harding, Simon P. ;
Lotery, Andrew J. ;
Downes, Susan M. ;
Chakravarthy, Usha ;
Reeves, Barnaby C. .
BMJ OPEN, 2014, 4 (07)
[6]   A systematic review on the quality, validity and usefulness of current cost-effectiveness studies for treatments of neovascular age-related macular degeneration [J].
Elshout, Mari ;
Webers, Carroll A. B. ;
van der Reis, Margriet I. ;
Schouten, Jan S. A. G. .
ACTA OPHTHALMOLOGICA, 2018, 96 (08) :770-778
[7]   Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy [J].
Ferrara, N ;
Hillan, KJ ;
Novotny, W .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (02) :328-335
[8]  
Khamar Bakulesh, 2007, Indian J Ophthalmol, V55, P411
[9]   Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial [J].
Kodjikian, Laurent ;
Souied, Eric H. ;
Mimoun, Gerard ;
Mauget-Faysse, Martine ;
Behar-Cohen, Francine ;
Decullier, Evelyne ;
Huot, Laure ;
Aulagner, Gilles .
OPHTHALMOLOGY, 2013, 120 (11) :2300-2309
[10]   A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration [J].
Krebs, Ilse ;
Schmetterer, Leopold ;
Boltz, Agnes ;
Told, Reinhard ;
Vecsei-Marlovits, Veronika ;
Egger, Stefan ;
Schoenherr, Ulrich ;
Haas, Anton ;
Ansari-Shahrezaei, Siamak ;
Binder, Susanne .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2013, 97 (03) :266-271
123